CN115605205A - 用于治疗或预防冠状病毒科感染的化合物以及用于评估冠状病毒科感染的发生的方法和用途 - Google Patents

用于治疗或预防冠状病毒科感染的化合物以及用于评估冠状病毒科感染的发生的方法和用途 Download PDF

Info

Publication number
CN115605205A
CN115605205A CN202180034076.4A CN202180034076A CN115605205A CN 115605205 A CN115605205 A CN 115605205A CN 202180034076 A CN202180034076 A CN 202180034076A CN 115605205 A CN115605205 A CN 115605205A
Authority
CN
China
Prior art keywords
coronaviridae
pharmaceutically acceptable
infection
acceptable salts
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034076.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·塔泽
H·埃尔利希
P·鲍雷蒂
J·桑托
D·谢雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wittycell
Original Assignee
Wittycell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20305299.8A external-priority patent/EP3881844A1/en
Priority claimed from EP20305327.7A external-priority patent/EP3884946A1/en
Application filed by Wittycell filed Critical Wittycell
Publication of CN115605205A publication Critical patent/CN115605205A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180034076.4A 2020-03-20 2021-03-19 用于治疗或预防冠状病毒科感染的化合物以及用于评估冠状病毒科感染的发生的方法和用途 Pending CN115605205A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20305299.8A EP3881844A1 (en) 2020-03-20 2020-03-20 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305299.8 2020-03-20
EP20305327.7A EP3884946A1 (en) 2020-03-25 2020-03-25 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305327.7 2020-03-25
EP20305482 2020-05-12
EP20305482.0 2020-05-12
EP20306483.7 2020-12-03
EP20306483 2020-12-03
PCT/EP2021/057123 WO2021186053A1 (en) 2020-03-20 2021-03-19 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection

Publications (1)

Publication Number Publication Date
CN115605205A true CN115605205A (zh) 2023-01-13

Family

ID=74884979

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034076.4A Pending CN115605205A (zh) 2020-03-20 2021-03-19 用于治疗或预防冠状病毒科感染的化合物以及用于评估冠状病毒科感染的发生的方法和用途

Country Status (11)

Country Link
US (1) US20230142547A1 (https=)
EP (1) EP4121053A1 (https=)
JP (1) JP2023521564A (https=)
KR (1) KR20220152292A (https=)
CN (1) CN115605205A (https=)
AU (1) AU2021238792A1 (https=)
BR (1) BR112022018793A2 (https=)
CA (1) CA3172179A1 (https=)
IL (1) IL296522A (https=)
MX (1) MX2022011596A (https=)
WO (1) WO2021186053A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024152743A1 (zh) * 2023-01-20 2024-07-25 江苏柯菲平医药股份有限公司 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
CN107635559A (zh) * 2015-02-23 2018-01-26 Abivax公司 用于治疗或预防病毒感染的喹啉衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225363A1 (en) 2003-11-21 2007-09-27 The University Of Newcastle Research Associates Ltd. Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2862928A1 (en) 2013-10-18 2015-04-22 Université de Strasbourg Dynamin 2 inhibitor for the treatment of centronuclear myopathies
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3858815A1 (en) * 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
CA3164700A1 (en) * 2020-01-31 2021-08-05 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
KR20210151949A (ko) * 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
CN107635559A (zh) * 2015-02-23 2018-01-26 Abivax公司 用于治疗或预防病毒感染的喹啉衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
""ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure inPatients With COVID-19"", pages 1 - 7, Retrieved from the Internet <URL:http//clinicaltrials.gov/ct2/nct04393038?V_1=view#studypagetop> *
TAO LIU等: ""The potential role of IL-6 in monitoring severe case of coronavirus disease 2019"", 《MEDRXIV》, 10 March 2020 (2020-03-10) *
ZHEN QIN等: ""miRNA-124 in Immune System and Immune Disorders"", 《FRONTIERS IN IMMUNOLOGY》, 4 October 2018 (2018-10-04), pages 1 - 8 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024152743A1 (zh) * 2023-01-20 2024-07-25 江苏柯菲平医药股份有限公司 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用

Also Published As

Publication number Publication date
JP2023521564A (ja) 2023-05-25
EP4121053A1 (en) 2023-01-25
AU2021238792A1 (en) 2022-10-13
BR112022018793A2 (pt) 2022-11-29
WO2021186053A1 (en) 2021-09-23
CA3172179A1 (en) 2021-09-23
KR20220152292A (ko) 2022-11-15
MX2022011596A (es) 2022-10-18
US20230142547A1 (en) 2023-05-11
IL296522A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
EP3500307B1 (en) Use of vcp inhibitor and oncolytic virus in the preparation of an anti-tumor drug
EP2825173B1 (en) Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
US20180263943A1 (en) Compound for treatment of myotonic dystrophy type 1
CN115605205A (zh) 用于治疗或预防冠状病毒科感染的化合物以及用于评估冠状病毒科感染的发生的方法和用途
US20250255871A1 (en) Systems and methods for treating cancer
US20160090636A1 (en) MicroRNA-129 AS A BIOMARKER FOR COLORECTAL CANCER
US10106853B2 (en) CUL4B as predictive biomarker for cancer treatment
HK40077570A (en) Compounds for treating or preventing a coronaviridae infection &amp; methods and uses for assessing the occurrence of a coronaviridae infection
US20060019972A1 (en) Methods of treating cancer by inhibiting histone gene expression
EP3884946A1 (en) Compounds for treating or preventing a coronaviridae infection &amp; methods and uses for assessing the occurrence of a coronaviridae infection
Fu et al. Dynamic change of shanks gene mRNA expression and DNA methylation in epileptic rat model and human patients
KR20210151944A (ko) 근육량 및 산화 대사를 증가시키기 위한 조성물 및 방법
CN114525342B (zh) Linc02806在肝细胞癌诊断和治疗中的应用
WO2023133414A2 (en) Selective elimination of senescent cells by ferroptosis induction
CN111635946B (zh) 一种诊治胶质瘤的分子生物标志物及其应用
US10517842B2 (en) Methods of modulating miRNA levels and compositions for use in the same
EP3881844A1 (en) Compounds for treating or preventing a coronaviridae infection &amp; methods and uses for assessing the occurrence of a coronaviridae infection
WO2021188578A1 (en) Screening methods to identify small molecule compounds that promote or inhibit the growth of circulating tumor cells, and uses thereof
US20250223560A1 (en) Nox4 inhibitor compositions and methods for regeneration of dystrophic muscle
US8697681B2 (en) Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
US20150104440A1 (en) MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER
EA046703B1 (ru) Ингибиторы киназы р38 снижают экспрессию dux4 и последующих генов для лечения fshd
CN121925261A (zh) 前列腺癌的治疗
CN121380284A (zh) Nsd2在肠道干细胞功能维持与衰老干预中的应用
WO2023078807A1 (en) A class iia hdac inhibitor and decitabine to treat myopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077570

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20230113